Philippa D. K. Curry
A5004638115- Rheumatoid Arthritis Research and Therapies
- Psoriasis: Treatment and Pathogenesis
- Spondyloarthritis Studies and Treatments
- Genomics and Rare Diseases
- Autoimmune and Inflammatory Disorders Research
- Medication Adherence and Compliance
- RNA modifications and cancer
- Genomic variations and chromosomal abnormalities
- Bipolar Disorder and Treatment
- Drug-Induced Adverse Reactions
- RNA Research and Splicing
- Cancer-related gene regulation
University of Manchester
2022-2024
Versus Arthritis
2022-2023
St George's, University of London
2021
Abstract Purpose of Review Whole exome sequencing (WES) and whole-genome (WGS) are frontline approaches for the genetic diagnosis rare diseases. However, WES/WGS fails in up to 75% cases. Transcriptomics via RNA-sequencing (RNA-Seq) is a novel approach that aims increase diagnostic yield Recent Findings publications focus on success RNA-Seq increasing rates WES/WGS-negative patients 36% cases, across range different diseases, sample sizes, tissue types. Summary beneficial aiding...
Abstract Background/Aims Despite NICE guidelines recommending the use of PsA response criteria (PsARC), to assess biologic therapies in patients with psoriatic arthritis (PsA), some clinicians Disease Activity Score (DAS-28) criteria, developed for rheumatoid arthritis. However, whether two scores are interchangeable and/or capture similar information has not yet been explored. Here, we investigate differences and overlap between these disease activity scores, identifying good/poor...
Up to 40% of psoriatic arthritis (PsA) patients experience first-line Tumour Necrosis Factor inhibitors (TNF-i) failure. Lower serum drug levels (SDL) have been associated with lower response in autoimmune conditions. This study aimed to: (i) establish the relationship between adalimumab (ADL) and etanercept (ETN) SDL 3-month response; (ii) identify optimal non-trough thresholds PsA.PsA commencing ADL or ETN were recruited UK observational OUTPASS. Patients seen pre-TNF-i at 3 months when...
Background In March 2020, as part of the UK’s COVID-19 prevention strategy, those identified ‘clinically extremely vulnerable’, were advised to shield. This included a number patients prescribed anti-rheumatic drugs, who asked continue their current treatment unless they developed symptoms infection. Suboptimal adherence (16.0%-81.0%) has been reported in with arthritic diseases, and is associated psychological factors, including anxiety (1). Previous literature non-UK cohorts highlighted...
Abstract Objective The aim of this study was to assess the relationship between self-reported non-adherence, non-trough drug levels, immunogenicity and conventional synthetic DMARD (csDMARD) co-therapy in TNF inhibitor (TNF-i) response PsA. Methods Serum samples adherence questionnaires were collected at baseline, 3, 6 12 months for PsA patients prescribed TNF-i. Non-trough adalimumab (ADL) etanercept (ETN) levels measured 3 using commercially available ELISAs. Clinical assessed criteria...
Abstract Background/Aims It is not currently possible to accurately predict tumour necrosis factor inhibitor (TNF-i) response in psoriatic arthritis (PsA). In rheumatoid arthritis, suboptimal adherence TNF-i and reduced drug levels have been associated with decreased response. Suboptimal treatment (16%-81%) has reported PsA although little known about the impact on Self-reported may be biased, but direct measurements offer an objective evaluation. The of this study assess relationship...